The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Aero flavours list️ In 2019, more than 10,000 cases were investigated and dealt with. Past stories of drug counterfeiting that were not shown on ...

Published first on TheFly – the ul The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

For many years, orphan drugs for rare diseases have been a draw for pharma companies, offering high prices, swift regulatory reviews, and often extended marketing exclusivity – but there are ...

Trikafta, a triple combination therapy for CF in patients with specific gene mutations, reaches endpoint in Phase III clinical trial The crisis of purchasing imported consumables in bulk in 10 provinc ...

Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...

Covalent peptide drugs can achieve high potency and selectivity with long dosing intervals, however, methods to discover them are limited. Here, the authors incorporate a genetically encoded ...